Tango Therapeutics (TNGX) to Release Earnings on Thursday
Tango Therapeutics (TNGX) is set to release its Q4 2025 earnings before market open on February 26th, with analysts forecasting an EPS of ($0.31). The company, trading at $12.41, has a "Moderate Buy" consensus rating and a target price of $14.80. Recent insider selling activity by Adam Crystal and CFO Daniella Beckman has been noted, while institutional investors have adjusted their stakes in the company.
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Tango Therapeutics (NASDAQ: TNGX) announced it will release its fourth-quarter 2025 financial results on March 5, 2026, without a conference call. Additionally, the company will participate in three investor conferences in March: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference. Webcasts of these events will be available on the company's website.
Tango Therapeutics to Report Fourth Quarter 2025 Financial
Tango Therapeutics announced it will report Q4 2025 financial results on March 5, 2026, and will participate in three upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, and Leerink Partners Global Healthcare Conference. The company, a clinical-stage biotechnology firm focused on precision cancer medicine, will provide webcasts for these events.
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Tango Therapeutics (NASDAQ: TNGX) announced it will report its fourth quarter 2025 financial results on March 5, 2026, before the U.S. financial markets open. The company also confirmed its management will participate in three upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference, taking place between March 4 and March 11, 2026. Live webcasts and replays for these events will be available on the company's website.
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Tango Therapeutics announced it will release its fourth-quarter 2025 financial results on March 5, 2026, without a conference call. The company also confirmed its management will participate in three investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference, where they will present and host meetings.
Readystate Asset Management LP Trims Holdings in Tango Therapeutics, Inc. $TNGX
Readystate Asset Management LP significantly reduced its stake in Tango Therapeutics (NASDAQ:TNGX) by 41.4% in the third quarter of last year, selling 173,408 shares and ending with 245,109 shares valued at $2.06 million. Despite this, institutional ownership remains high at 78.99%, and several other firms increased their positions. Analysts maintain a "Moderate Buy" rating for TNGX with a consensus price target of $14.80.
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Tango Therapeutics (NASDAQ: TNGX) announced it will report its fourth-quarter 2025 financial results on March 5, 2026. The company also confirmed its participation in three investor conferences: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference, with webcasts available for each event. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicine for cancer treatment.
Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX)
Tango Therapeutics (TNGX) recently announced plans for a pivotal 300-patient randomized trial for vopimetostat in second-line pancreatic cancer, following positive FDA interactions. This development, alongside preclinical synergy with RAS inhibitors and progress on CNS agent TNG456, could significantly alter the investment narrative for the precision oncology company. However, the company remains unprofitable, trades at a high sales multiple, and faces execution risks inherent in high-risk oncology trials, especially given its recent stock performance and shareholder dilution.
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat
Tango Therapeutics CEO Malte Peters announced plans for a pivotal 300-patient randomized trial for vopimetostat in second-line pancreatic cancer this year, following positive interactions with the FDA. The company is also evaluating vopimetostat in combination with Revolution Medicines' RAS inhibitors, showing promising preclinical synergy and strong early enrollment. Additionally, Tango's pipeline includes the CNS agent TNG456 nearing data release and further exploration of vopimetostat in MTAP-deleted cancers with early positive signals.
Tango Therapeutics stock hits 52-week high at $13.47
Tango Therapeutics Inc. (TNGX) stock recently hit a new 52-week high of $13.47, reflecting a significant 404.78% increase over the past year. Despite its strong market performance, including an 84.16% gain over six months, InvestingPro suggests the company might be overvalued with negative gross profit margins, facing challenges despite revenue growth. The company has also announced leadership changes and a $100 million at-the-market stock offering, while Stifel maintains a Buy rating with a $15.00 price target.
Insiders At Tango Therapeutics Sold US$727k In Stock, Alluding To Potential Weakness
Insiders at Tango Therapeutics, Inc. (NASDAQ:TNGX) sold US$727k worth of shares over the last year, with no insider purchases recorded. The largest sale was by Founder & Executive Chair, Barbara Weber, for US$374k. While insider ownership stands at 1.3%, the consistent selling by insiders suggests a potential lack of confidence in the stock's current valuation, prompting a cautious outlook for investors.
TNGX: Pivotal and combination trial data for vopimetostat, plus pipeline updates, are expected this year
Tango Therapeutics (TNGX) is focusing on advancing vopimetostat towards regulatory approval, with key trials in pancreatic and lung cancer progressing. Pivotal and combination data for vopimetostat, along with pipeline updates for TNG456 and TNG961, are anticipated this year. This information is based on their Guggenheim Securities Emerging Outlook: Biotech Summit 2026 audio transcript.
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Moderate Buy" by Brokerages
Eight brokerages have given Tango Therapeutics (NASDAQ:TNGX) an average rating of "Moderate Buy," with a 12-month average price target of $14.80. The stock recently opened at $12.51, nearing its 52-week high, and has a market capitalization of $1.68 billion. Insider transactions show recent sales by Adam Crystal and Barbara Weber, while institutional investors have adjusted their holdings.
Guggenheim Keeps Their Buy Rating on Tango Therapeutics (TNGX)
Guggenheim analyst Michael Schmidt reiterated a Buy rating for Tango Therapeutics (TNGX) with an $18.00 price target, following the company's Q3 earnings report showing significant revenue growth and net profit. Despite increased insider selling, the overall analyst consensus remains a Strong Buy.
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Tango Therapeutics announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The event will be webcast live and archived on the company's investor relations website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer treatment.
Guggenheim Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price
Guggenheim has raised its price target for Tango Therapeutics (NASDAQ:TNGX) from $12.00 to $18.00, maintaining a "buy" rating and suggesting a potential 42% upside. The company surpassed earnings and revenue estimates in its last quarter, though it remains unprofitable. Insider sales totaling approximately $726,871 have occurred in the last 90 days, while institutional investors hold nearly 79% of the stock.
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 18,452 Shares of Stock
Tango Therapeutics (NASDAQ:TNGX) insider Adam Crystal sold 18,452 shares of the company's stock for approximately $226,222 on February 3rd, reducing his stake by nearly 9%. Despite this insider selling, TNGX recently outperformed analyst revenue and EPS estimates, though it remains unprofitable. The stock currently holds a "Moderate Buy" consensus rating from analysts, with a mean price target around $13.60.
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Director Sells 30,519 Shares of Stock
Tango Therapeutics Director Barbara Weber sold 30,519 shares of TNGX stock for approximately $374,163 on February 3rd, reducing her ownership by 1.84%. The company's stock traded down 1.8% to $12.32, with a market capitalization of $1.66 billion. Tango Therapeutics recently beat quarterly EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $13.60.
Weber Barbara, director at Tango Therapeutics, sells $374k in TNGX stock
Tango Therapeutics director, Weber Barbara, sold 30,519 shares of TNGX common stock for approximately $374,293 on February 3, 2026. This transaction follows her acquisition of 37,522 shares and 222,132 stock options a day earlier. The company also announced a $100 million at-the-market stock offering and several leadership changes, including Malte Peters becoming the new CEO and Barbara Weber transitioning to Executive Chair.
Commit To Purchase Tango Therapeutics At $10, Earn 25.9% Annualized Using Options
Investors considering Tango Therapeutics Inc (TNGX) shares at $11.97 may explore selling a December put option at the $10 strike for a potential 25.9% annualized return. This strategy offers a significant premium but means the investor only acquires shares if the price drops below $10. The article highlights the stock's historical volatility and the potential reward-to-risk of this options strategy.
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Tango Therapeutics announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. A live webcast and subsequent replay will be available on the company's website. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer using the principle of synthetic lethality.
Can Tango Therapeutics (TNGX) climb 37.28% to reach the level Wall Street analysts expect?
This article discusses whether Tango Therapeutics (TNGX) can achieve the 37.28% increase predicted by Wall Street analysts. It highlights the stock's current trading position relative to its average analyst-backed target price.
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Tango Therapeutics (NASDAQ: TNGX) announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The event is scheduled for Thursday, February 12, 2026, at 2:00 PM EST. A live webcast and subsequent replay will be available on the "Investors" page of the company's website.
Great Lakes Advisors LLC Invests $3.56 Million in Tango Therapeutics, Inc. $TNGX
Great Lakes Advisors LLC recently acquired a new stake worth $3.56 million in Tango Therapeutics (NASDAQ:TNGX) during the third quarter, signaling institutional confidence in the biotechnology company. Analysts hold a "Moderate Buy" consensus rating for Tango Therapeutics, with an average price target of $13.60, and several firms have raised their targets recently. Despite operating unprofitably with negative margins, Tango Therapeutics exceeded earnings and revenue estimates in its latest reported quarter.
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd
The Pancreatic Cancer market is projected for significant growth through 2034, driven by increasing disease prevalence, awareness, and the launch of multi-stage pipeline products. Several biopharmaceutical companies are advancing new therapies, with recent developments including Orphan Drug Designations and successful clinical trial outcomes for various pancreatic cancer treatments. The report highlights key companies and therapies, focusing on advancements and market trends in the US, EU5, and Japan.
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd
DelveInsight's report forecasts significant growth in the Pancreatic Cancer market through 2034, driven by increasing disease prevalence, awareness, and a robust pipeline of therapies from companies like AstraZeneca, Merck Sharp & Dohme, Dragonfly Therapeutics, and others. The report highlights recent advancements, including several Orphan Drug Designations and clinical trial milestones. Pancreatic cancer remains highly lethal, indicating an urgent need and large market opportunity for new and effective treatments, especially for advanced stages.
A Look At Tango Therapeutics (TNGX) Valuation After CEO Transition And Strong Recent Share Price Returns
Tango Therapeutics (TNGX) recently underwent a CEO transition, with Dr. Barbara Weber retiring and Dr. Malte Peters taking over. This leadership change follows significant share price momentum, including a 45.13% return over one month and a 66.14% return over three months. Despite strong performance and a 1-year total shareholder return of over 3x, the company's valuation appears high with a Price to Sales ratio of 25.3x, significantly above its peers and estimated fair value, suggesting it may be overvalued given its current net loss.
A Look At Tango Therapeutics (TNGX) Valuation After CEO Transition And Strong Recent Share Price Returns
Tango Therapeutics (TNGX) is under scrutiny after its founding CEO retired and was replaced by a board member, following a period of significant share price appreciation. The article examines the company's valuation, noting its high P/S ratio of 25.3x compared to peers and the industry average, suggesting it may be overvalued despite recent gains. Investors are advised to consider the company's net loss and reliance on successful clinical progress when assessing its future growth potential.
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues
Tango Therapeutics (NASDAQ:TNGX) recently experienced a 53% share price jump, leading to a high price-to-sales (P/S) ratio of 26.3x, significantly above the biotech industry average. Despite strong past revenue growth, future analyst estimates project only 0.2% annual growth for the company, compared to 126% for the industry, suggesting its current elevated P/S may be unjustified. The article warns investors to be cautious as the high valuation might fall if revenue sentiment does not improve.
Is Tango Therapeutics’ New CEO (TNGX) Quietly Redefining Its Clinical Strategy And Execution Priorities?
Tango Therapeutics recently appointed Malte Peters, M.D., as its new President and CEO, signaling a focus on clinical execution and corporate development. While this leadership change is seen as an evolution rather than a disruption, the company's investment narrative still hinges on its precision oncology pipeline, despite ongoing losses and a high sales multiple. Investors are advised to consider the potential overvaluation and dilution risks alongside the clinical promise.
Tango Therapeutics stock hits 52-week high at 12.65 USD By Investing.com
Tango Therapeutics (TNGX) stock has hit a new 52-week high of $12.67, representing a 320.5% return over the past year. The biotechnology company, focused on cancer therapies, has a market cap of $1.69 billion and analysts maintain a "Strong Buy" rating despite projections of continued losses for the fiscal year. This growth is supported by positive market sentiment, clinical program advancements, a recent $100 million stock offering, and positive analyst outlooks, alongside leadership changes.
Tango Therapeutics stock hits 52-week high at 12.65 USD
Tango Therapeutics (TNGX) stock has reached a new 52-week high of $12.67, representing a 320.5% return over the past year. Despite analysts projecting continued losses this fiscal year, the biotechnology company, focused on cancer therapies, commands a market capitalization of $1.69 billion and has a "Strong Buy" consensus. Recent corporate activities include a $100 million at-the-market stock offering, maintained "Buy" rating from Stifel, and leadership changes with Malte Peters appointed as CEO.
Tango Therapeutics stock hits 52-week high at 12.65 USD
Tango Therapeutics (TNGX) stock has reached a new 52-week high of $12.67, representing a 320.5% return over the past year. The biotechnology company, focused on cancer treatment, has a market capitalization of $1.69 billion and a "Strong Buy" analyst consensus. Despite impressive revenue growth, analysts project continued losses this fiscal year, with the stock trading above its Fair Value according to InvestingPro.
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week High - Here's Why
Tango Therapeutics (NASDAQ:TNGX) stock hit a new 52-week high of $12.52 on Thursday, trading on heavy volume with a market cap of $1.67 billion. Analysts maintain a "Moderate Buy" consensus with an average price target of $13, following the company's beat on quarterly earnings and revenue estimates. Despite being unprofitable, the stock has seen recent upgrades and price target increases from several research firms.
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Eight analysts have given Tango Therapeutics, Inc. (NASDAQ:TNGX) a consensus recommendation of "Moderate Buy," with an average 12-month target price of $13.00. The company recently reported an EPS beat of $0.13 and revenue of $53.8 million, leading to an 18.7% jump in shares, but analysts still forecast a negative EPS for the year. Institutional investors hold a significant stake in TNGX, despite recent insider selling.
Tango Therapeutics (TNGX) Valuation Check After Leadership Reshuffle And Strong Recent Share Price Performance
Tango Therapeutics (TNGX) recently underwent a leadership change, with Dr. Malte Peters taking over as CEO and president, following a strong 35.86% share price increase in the past month. Despite this momentum and trading near an analyst target of $13.25, the company's valuation, evidenced by a Price-to-Sales (P/S) ratio of 25.1x against a peer average of 9.3x and an estimated fair P/S of 1.9x, suggests it may be overvalued. This high valuation, coupled with ongoing losses, indicates potential risks if clinical or partnership setbacks occur.
TNGX: Leadership shift supports late-stage trials and robust MTAP-deleted cancer pipeline progress
Tango Therapeutics (TNGX) has shifted its leadership to Malte Peters, aiming to advance late-stage trials for its MTAP-deleted cancer pipeline. The company plans to reach key milestones in 2026, including pivotal trials and combination studies, supported by a strong financial position and strategies aligned with the FDA. This strategic move is expected to accelerate the development of their cancer treatments.
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data
Stifel has maintained its Buy rating and $15.00 price target on Tango Therapeutics Inc. (NASDAQ:TNGX) after the company provided pipeline updates and strategic priorities for 2026. This positive outlook is supported by "encouraging" early efficacy data for vopimetostat in combination with RAS(ON) inhibitor, with Stifel anticipating a swift move into a Phase 3 study. Despite positive market sentiment and significant stock returns, InvestingPro analysis indicates the stock is trading above its Fair Value.
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4% - What's Next?
Tango Therapeutics (NASDAQ:TNGX) saw its stock price drop 8.4% during mid-day trading with unusually low volume. Despite beating recent earnings estimates, the company still has a negative net margin. Analysts have a "Moderate Buy" consensus rating with an average target price of $13.00, and institutional investors have been actively trading the stock.
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data
Stifel maintained its Buy rating and a $15.00 price target for Tango Therapeutics (NASDAQ: TNGX) after the company provided pipeline updates and strategic priorities for 2026. The positive sentiment is driven by encouraging early efficacy data for its vopimetostat plus RAS(ON) inhibitor combination study, potentially leading to a swift move to a Phase 3 study for pancreatic cancer. Despite the positive outlook from analysts, InvestingPro noted that the stock is trading above its Fair Value with a high Price/Book ratio and negative EBITDA.
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 29%
Tango Therapeutics (TNGX) shares have seen a significant surge, gaining 29% in the last month and 302% over the past year. Despite this strong performance, the company's price-to-sales (P/S) ratio of 23.8x is considerably higher than industry peers, raising concerns given its subdued revenue growth forecasts. Analysts predict a mere 0.3% annual growth for Tango Therapeutics over the next three years, contrasting sharply with the broader industry's 122% forecast.
Tango Therapeutics Appoints Dr. Malte Peters as CEO
Tango Therapeutics (NASDAQ: TNGX) has announced the retirement of its founding CEO, Dr. Barbara Weber, who will transition to Executive Chair. Dr. Malte Peters, a current board member with extensive clinical development experience, has been appointed as the new President and CEO. Dr. Weber will continue to support the company's strategic priorities and ensure a smooth transition, while Dr. Peters will lead Tango into its next phase, focusing on advancing its pipeline, including the registrational trial for vopimetostat.
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Tango Therapeutics announced that its founding CEO, Barbara Weber, M.D., will retire, effective January 8, 2026, transitioning to Executive Chair for 2026 and then non-executive chair in 2027. Malte Peters, M.D., a current board member with extensive clinical development experience, has been appointed as the new President and Chief Executive Officer. The company also reiterated its anticipated clinical milestones for 2026, including initial safety and efficacy data for vopimetostat combination trials, a lung cancer update for vopimetostat monotherapy, the start of a pivotal study for vopimetostat in pancreatic cancer, and initial data for TNG456 monotherapy.
Assessing Tango Therapeutics (TNGX) Valuation After Strong Share Price Momentum
Tango Therapeutics (TNGX) has experienced significant share price growth, with a 179% return over the past year. Despite this momentum and a high 19.6x Price-to-Sales (P/S) ratio, which is above industry averages, the company remains unprofitable and is not forecasted to become profitable within the next three years. The article suggests that while revenue growth is projected in the mid-40% range, the current valuation seems overvalued compared to its estimated fair P/S of 1.8x, cautioning investors about potential risks like ongoing losses and clinical trial failures.
Cancer drug developer Tango brings in new leader as trials advance
Tango Therapeutics (NASDAQ: TNGX) announced a leadership transition, with founding CEO Barbara Weber, M.D. retiring and Malte Peters, M.D. appointed as the new President and CEO. Weber will transition to Executive Chair for 2026 before becoming non-executive chair in 2027, ensuring continuity. The company also reiterated key clinical milestones for 2026, including data readouts for multiple vopimetostat trials and the start of a pivotal study for 2L pancreatic cancer.
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Tango Therapeutics announced that its founding CEO, Dr. Barbara Weber, is retiring, effective January 8, 2026. She will transition to Executive Chair for 2026 and then non-executive chair in 2027. Dr. Malte Peters, a current board member with extensive clinical development experience, has been appointed as the new President and Chief Executive Officer.
Assessing Tango Therapeutics (TNGX) Valuation After Strong Share Price Momentum
Tango Therapeutics (TNGX) has experienced significant share price growth, with a 179% total return over the past year. Despite this momentum, the company's Price-to-Sales (P/S) ratio of 19.6x is considerably higher than industry averages, suggesting overvaluation, especially given its unprofitability and ongoing losses. While revenue is projected to grow, the high P/S indicates investors are paying a premium, and the company faces risks associated with clinical trial outcomes.
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com
Tango Therapeutics (NASDAQ:TNGX) has appointed Sung Lee to its Board of Directors. Lee brings over two decades of finance leadership experience from the biopharmaceutical and technology sectors and currently serves as CFO at Cytokinetics. His appointment comes as Tango Therapeutics advances its lead program, vopimetostat, into registrational studies, supported by positive clinical data and analyst optimism.
Tango Therapeutics appoints Sung Lee to board of directors
Tango Therapeutics (NASDAQ:TNGX) has appointed Sung Lee to its Board of Directors, leveraging his two decades of finance leadership in the biopharmaceutical and technology sectors. Lee's extensive experience, including CFO roles at several biotech companies and 14 years at Gilead Sciences, is expected to be instrumental as Tango advances its lead program, vopimetostat, into registrational studies. The appointment follows a significant 183.49% return for TNGX shares over the last year, although the stock shows high volatility.
Tango Therapeutics adds independent director to strengthen governance
Tango Therapeutics has appointed a new independent director to its board. This move aims to strengthen the company's governance and strategic oversight. The addition is expected to support Tango Therapeutics' ongoing development and objectives.
